Lucid Diagnostics News

Press Release: PAVmed Provides Business Update and First Quarter 2024 Financial Results

PAVmed Provides Business Update and First Quarter 2024 Financial Results PR Newswire NEW YORK, May 13, 2024 Lucid strengthens balance sheet and secures a July 17, 2024 MolDX pre-submission meeting

Dow Jones20:43 ET

Express News | Needham Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

BenzingaMay 13 11:50 ET

Analysts Offer Insights on Healthcare Companies: Adicet Bio (ACET), Jasper Therapeutics (JSPR) and Lucid Diagnostics (LUCD)

TipRanksMay 13 11:50 ET

Lucid Diagnostics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 171.74% Needham → $2.5 Reiterates Buy → Buy 04/12/2024 171.74% Needham → $2.5 Reiterates Buy →

BenzingaMay 13 11:45 ET

Express News | Corrected-Lucid Diagnostics Inc: Qtrly Adj Shr Loss $0.21 (Adds Dropped Word 'adj')

ReutersMay 13 09:23 ET

Express News | Lucid Diagnostics Inc Q1 Shr View $-0.27 -- Lseg Ibes Data

ReutersMay 13 08:27 ET

Express News | Lucid Diagnostics Inc: Qtrly Shr Loss $0.21

ReutersMay 13 08:27 ET

Lucid Diagnostics | 10-Q: Quarterly report

SEC announcementMay 13 08:24 ET · Announcements

Express News | Lucid's Chairman And CEO Says We Strengthened Balance Sheet Closing ~$30M Preferred Stock Financing To Long-Term Investors; Extends Our Runway Past Milestones; EsoGuard Commercial Execution Continues To Deliver Results As We Drive Towards Expanded...

BenzingaMay 13 08:08 ET

Lucid Diagnostics 1Q Loss $18.1M >LUCD

Lucid Diagnostics 1Q Loss $18.1M >LUCD

Dow JonesMay 13 08:06 ET

Lucid Diagnostics 1Q Loss/Shr 40c >LUCD

Lucid Diagnostics 1Q Loss/Shr 40c >LUCD

Dow JonesMay 13 08:06 ET

Lucid Diagnostics Q1 2024 Adj EPS $(0.21) Beats $(0.27) Estimate, Sales $1.001M Miss $1.046M Estimate

Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.27) by 22.22 percent. This is a 12.5 percent increase over losses of $(0

BenzingaMay 13 08:03 ET

Express News | Lucid Diagnostics Says EsophaCap Device Recalled Due To Recent Publication Of Serious Device Failures

BenzingaMay 9 08:23 ET

Express News | Lucid Diagnostics Inc - Esophacap Device Recalled Due to Recent Publication of Serious Device Failures

ReutersMay 9 07:53 ET

Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...

PR NewswireMay 9 07:49 ET

Lucid Diagnostics Raises $11.6M Through Preferred Stock Sale

TipRanksMay 7 08:02 ET

Express News | Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

ReutersMay 7 07:39 ET

Lucid Diagnostics Highlights Promising EsoGuard Study Results

TipRanksMay 2 17:12 ET

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024

Conference Call and Webcast at 8:30AM Eastern Time NEW YORK, May 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical

PR NewswireMay 2 08:35 ET

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data From National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing

EsoGuard demonstrated unprecedented early precancer detection, including 89% sensitivity at detecting short segment early precancer, the primary target of esophageal precancer testing Publication fur

PR NewswireMay 2 07:49 ET